vimarsana.com
Home
Live Updates
ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Pr
ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Pr
ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease
Anavex Life Sciences Corp. announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 for the treatment of mild cognitive impairment due to... | December 2, 2022
Related Keywords
San Francisco ,
California ,
United States ,
,
Anavex Life Sciences Corp ,
Anavex Life Sciences ,
Clinical Trials ,
Odds Ratio ,
Clinical Dementia Rating Scale Sum ,
Anavex Life Sciences Corp Stock Exchange ,
News ,
Information ,
Press Release ,
Navex ,
Life ,
Ciences ,
Nnounced ,
Positive ,
Topline ,
Results ,
Rom ,
Its ,
Hase ,
Linical ,
Trial ,
F ,
Mural ,
Or ,
The ,
Treatment ,
Ild ,
Cognitive ,
Impairment ,
Ue Avxl Us0327973006 ,